Breaking News Bar
updated: 9/9/2013 10:42 AM

Sagent offers 4 million shares of stock

hello
Success - Article sent! close
 
Globe Newswire

SCHAUMBURG -- Injection drugmaker Sagent Pharmaceuticals announced it will hold a public offering of almost 4.4 million shares of common stock.

The company will offer 3,384,097 shares and current shareholders will be offer an additional 1,057,530 shares of common stock. In addition, selling shareholders, collectively, intend to grant underwriters a 30-day option to purchase up to an additional 666,244 shares of common stock, all at the public offering price less the underwriter discount.

Order Reprint Print Article
 
Interested in reusing this article?
Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.
The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.
Need more information about reprints? Visit our Reprints Section for more details.

Contact information ( * required )

Success - request sent close

The company said it intends to use the proceeds for general corporate purposes, which includes funding working capital, operating expenses, the continued development of its products and portfolio, maintenance and expansion of its current collaboration arrangements, the strengthening of its existing commercial organization, funding the final payments for the remaining 50 percent interest in Sagent (China) Pharmaceuticals Co. Ltd. and any costs related to its manufacturing facility, and the selective pursuit of business development opportunities in its focus segment areas. The Company will not receive any of the proceeds from the sale of shares by the selling stockholders, including the shares to be sold by the selling stockholders if the underwriters exercise their over-allotment option.

Morgan Stanley, Jefferies and BofA Merrill Lynch are acting as joint book-running managers for the offering, and Piper Jaffray & Co. and Needham & Company, LLC are acting as co-managers.

Share this page
Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.
    help here